Physician profile
Paul Potach
NPI 1073627410
$45,035.22
in general payments reported to CMS, 2019-2025
12 companies · $42K in 2025
The $42K reported for 2025 was more than what 99% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.34 · 2020: $170 · 2021: $323 · 2022: $1,287 · 2023: $705 · 2024: $835 · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $41K · Food and Beverage: $2,422 · Consulting Fee: $13.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $40,764.00 |
| Food and Beverage | $2,422.22 |
| Consulting Fee | $13.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $40,764.00 | 2025 | |
| Organogenesis INC. | $3,343.20 | 2021-2025 | Puraply, Simplimax, Cygnus Dual |
| Horizon Therapeutics Plc | $484.84 | 2019-2022 | |
| Cardiovascular Systems INC. | $166.25 | 2022 | |
| Nevro Corp. | $145.81 | 2024 | Senza |
| Next Science LLC | $58.74 | 2023-2024 | Blastx, Xperience, Surgx |
| Smith+Nephew, INC. | $15.00 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.09 | 2022 | |
| Ibsa Pharma INC. | $13.34 | 2023 | Licart, Tirosint |
| Novum Pharma, LLC | $11.87 | 2019 | |
| Orthofix Medical, INC. | $10.74 | 2019 | |
| Grt US Holding, INC. | $7.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Potach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.